Postdoctoral Research Training in Pediatric Clinical Pharmacology

儿科临床药理学博士后研究培训

• 批准号: 8843495
• 负责人: DAVID Alastair FLOCKHART
• 金额: $ 18.4万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8843495
• 关键词: Childhood; Clinical Pharmacology; Research Training

DESCRIPTION (provided by applicant): A critical need exists for a robust supply of clinician scientists with formal training in pediatric clinical pharmacology. Without trained investigators the goal of optimizing use of medications for individual children cannot be realized. The Indiana University Department of Pediatrics and Division of Clinical Pharmacology are uniquely positioned to address this need. A strong, well-established group of clinical pharmacology investigators has the advantage of being located directly adjacent to one of the strongest pediatric research environments in the US: Riley Hospital for Children, with a Department of Pediatrics consistently ranked in the top 10 in NIH funding. This application seeks to establish a formal pediatric clinical pharmacology and therapeutics training program in parallel with our long-standing clinical pharmacology training program, which has a track record of excellence in training successful translational clinician scientists. There are three main components to the Indiana University Postdoctoral Research Training in Pediatric Clinical and Developmental Pharmacology: 1) completion of a two to three year formal didactic curriculum, at the end of which the trainee may receive a master's degree in clinical research; 2) organized pediatric participation in a personalized therapeutics seminar series and weekly journal club; and 3) active involvement in pediatric therapeutics research under the mentorship of one of the faculty members associated with the program. The program faculty selects trainees for the 2 to 3 year program based on their potential as clinician scientists from candidates with MD or MD/ PhD degrees who qualify for primary specialty certification. Exceptional PhD or PharmD candidates with experience and goals related to the objectives of the program may be selected. We propose supporting a total of three postdoctoral fellows at any given time. Those who complete the program will develop core competencies in clinical and translational research methods, biostatistics, clinical trials, research ethics, scientific writing, and grant writing. They will also be provided with a structured research mentoring program with an explicit timeline and benchmarks. In depth training focusing on pharmacokinetics, pharmacogenomics, drug development, individualized therapeutics, and clinical trial design is included in a didactic lecture series required of all trainees. Trainees may also participate in the Clinical Investigator Training Enhancement program supported by the Indiana CTSI and resulting in an MS in Clinical Investigation. Coursework combined with supervised research experience will result in development of a highly trained cadre of investigators with broad, deep, cutting edge training experiences preparing them for successful careers in pediatric clinical and translational pharmacology. The large, diverse patient population at Riley Hospital coupled with the depth, breadth and flexibility imparted by a large, cutting edge Clinical Pharmacology training program and the Wells Center for Pediatric Research offer an exceptional opportunity to study pediatric clinical pharmacology within a focused training program designed to generate leaders in this emerging field.

描述（由申请方提供）：迫切需要提供大量接受过儿科临床药理学正规培训的临床科学家。如果没有经过培训的研究人员，就无法实现为个别儿童优化药物使用的目标。印第安纳州大学儿科系和临床药理学系具有独特的优势来满足这一需求。一个强大的，完善的临床药理学研究小组的优势是直接毗邻美国最强大的儿科研究环境之一：莱利儿童医院，儿科一直在NIH资助中排名前10位。本申请旨在建立一个正式的儿科临床药理学和治疗学培训计划，与我们长期的临床药理学培训计划并行，该计划在培训成功的转化临床医生科学家方面具有卓越的记录。印第安纳州大学儿科临床和发育药理学博士后研究培训主要有三个组成部分：1）完成两到三年的正式教学课程，结束时受训者可以获得临床研究硕士学位; 2）组织儿科参与个性化治疗研讨会系列和每周期刊俱乐部;和3）在与该项目相关的一名教职员工的指导下积极参与儿科治疗学研究。该计划的教师选择学员为2至3年的计划，根据他们的潜力作为临床科学家从候选人与MD或MD/博士学位谁有资格获得主要专业认证。可以选择具有与计划目标相关的经验和目标的特殊博士或药学博士候选人。我们建议在任何时候支持总共三名博士后研究员。那些谁完成该计划将开发在临床和转化研究方法，生物统计学，临床试验，研究伦理，科学写作和赠款写作的核心竞争力。他们还将获得一个有明确时间轴和基准的结构化研究指导计划。在深入的培训，重点是药代动力学，药物基因组学，药物开发，个性化治疗和临床试验设计是包括在所有学员所需的教学讲座系列。受训者还可以参加由印第安纳州CTSI支持的临床研究者培训增强计划，并获得临床研究硕士学位。课程与监督研究经验相结合，将导致一个训练有素的干部的研究人员与广泛，深入，尖端的培训经验，准备他们在儿科临床和转化药理学的成功职业生涯的发展。莱利医院的大型，多样化的患者人群，加上大型，尖端临床药理学培训计划和威尔斯儿科研究中心所赋予的深度，广度和灵活性，提供了一个特殊的机会，在一个旨在培养这一新兴领域领导者的集中培训计划中学习儿科临床药理学。